Department of Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio; Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Bostons, Massachusetts.
JACC Heart Fail. 2017 Sep;5(9):642-651. doi: 10.1016/j.jchf.2017.05.012. Epub 2017 Aug 16.
This study examined the association of aldosterone and plasma renin activity (PRA) with incident cardiovascular disease (CVD), using a composite endpoint of coronary heart disease, stroke, and/or heart failure and mortality among African Americans in the Jackson Heart Study.
There is a paucity of data for the association of aldosterone and PRA with incident CVD or all-cause mortality among community-dwelling African Americans.
A total of 4,985 African American adults, 21 to 94 years of age, were followed for 12 years. Aldosterone, PRA, and cardiovascular risk factors were collected at baseline (from 2000 to 2004). Incident events included coronary heart disease and stroke (assessed from 2000 to 2011) and heart failure (assessed from 2005 to 2011). Cox models were used to estimate hazard ratios (HRs) for incident CVD and mortality, adjusting for age, sex, education, occupation, current smoking, physical activity, dietary intake, and body mass index.
Among 4,160 participants without prevalent CVD over a median follow-up of 7 years, there were 322 incident CVD cases. In adjusted analyses, each 1-U SD increase in log-aldosterone and log-PRA were associated with HR of 1.26 (95% confidence intervals [CI]: 1.14 to 1.40) and 1.16 (95% CI: 1.02 to 1.33) for incident CVD, respectively. Over a median of 8 years, 513 deaths occurred among 4,985 participants. In adjusted analyses, each 1-U SD increase in log-aldosterone and log-PRA were associated with HRs of 1.13 (95% CI: 1.04 to 1.23) and 1.12 (95% CI: 1.01 to 1.24) for mortality, respectively.
Elevated aldosterone and PRA may play a significant role in the development of CVD and all-cause mortality among African Americans.
本研究使用冠心病、卒中和/或心力衰竭及全因死亡率的复合终点,探讨醛固酮和血浆肾素活性(PRA)与非裔美国人心血管疾病(CVD)事件的相关性,该研究来自于杰克逊心脏研究。
在社区居住的非裔美国人中,醛固酮和 PRA 与 CVD 事件或全因死亡率的相关性数据较少。
共有 4985 名年龄在 21 至 94 岁的非裔美国成年人参与了本研究,随访时间为 12 年。在基线时(2000 年至 2004 年)收集了醛固酮、PRA 和心血管危险因素数据。事件包括冠心病和卒中等(2000 年至 2011 年评估)以及心力衰竭(2005 年至 2011 年评估)。Cox 模型用于估计 CVD 事件和死亡率的风险比(HR),调整了年龄、性别、教育程度、职业、当前吸烟、体力活动、饮食摄入和体重指数。
在中位随访 7 年期间无 CVD 病史的 4160 名参与者中,有 322 例发生 CVD 事件。在调整后的分析中,醛固酮和 PRA 的每 1 个标准差增加与 CVD 事件的 HR 分别为 1.26(95%置信区间[CI]:1.14 至 1.40)和 1.16(95% CI:1.02 至 1.33)。在中位随访 8 年期间,在 4985 名参与者中共有 513 人死亡。在调整后的分析中,醛固酮和 PRA 的每 1 个标准差增加与死亡率的 HR 分别为 1.13(95% CI:1.04 至 1.23)和 1.12(95% CI:1.01 至 1.24)。
醛固酮和 PRA 的升高可能在非裔美国人 CVD 和全因死亡率的发生中起重要作用。